文献速递前列腺癌

英国年轻起病前列腺癌病例的胚系DNA修复基因突变:支持更广泛的基因检测组合

Germline DNA Repair Gene Mutations in Young-onset Prostate Cancer Cases in the UK: Evidence for a More Extensive Genetic Panel.
PubMed 文献 · Eur Urol · 2019-02-15

该研究对英国1281例年轻起病前列腺癌病例(诊断年龄≤60岁)和1160名对照的167个DNA修复基因及8个前列腺癌候选基因进行测序,发现病例组蛋白截短变异携带者比例高于对照组(15% vs 12%,OR=1.29,95%CI 1.01-1.64,p=0.036),并识别出23个与前列腺癌易感或侵袭性疾病风险相关的DNA修复基因。

要点

  • 年轻起病前列腺癌病例的蛋白截短变异携带者比例高于对照(15% vs 12%,OR=1.29,95%CI 1.01-1.64,p=0.036)。
  • 基因水平分析选出NBN与总体风险相关(pSKAT-O=2.4×10-4),XPC与侵袭性疾病相关(pSKAT-O=1.6×10-4)。
  • 基因集分析识别20个基因与前列腺癌风险增加相关(OR=3.2,95%CI 2.1-4.8),4个基因与侵袭性疾病风险增加相关(OR=11.2,95%CI 4.6-27.7)。

核心结论

  • 基因水平和基因集水平分析的并集识别出23个与前列腺癌易感或侵袭性疾病风险相关的DNA修复基因。
  • 这些发现有助于开发具有预测和预后潜力的前列腺癌特异性测序组合。

研究设计与样本

  • 在英国基于人群的队列中,对1281例年轻起病前列腺癌病例(诊断年龄≤60岁)和1160名选择的对照进行167个DNA修复基因及8个前列腺癌候选基因测序。

主要发现

  • 在97个基因中识别出233个独特的蛋白截短变异(PTVs),在对照中次要等位基因频率<0.5%。
  • PTV携带者总比例病例组高于对照组(15% vs 12%,OR=1.29,95%CI 1.01-1.64,p=0.036)。
  • 基因水平分析选出NBN(pSKAT-O=2.4×10-4)与总体风险相关,XPC(pSKAT-O=1.6×10-4)与侵袭性疾病相关,均达到候选水平显著性(分别为p<3.1×10-4和p<3.4×10-4)。
  • 基因集分析识别出20个基因与前列腺癌风险增加相关(OR=3.2,95%CI 2.1-4.8,pADA=4.1×10-3),4个基因与侵袭性疾病风险增加相关(OR=11.2,95%CI 4.6-27.7,pADA=5.6×10-3),其中3个与易感基因集重叠。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Rare germline mutations in DNA repair genes are associated with prostate cancer (PCa) predisposition and prognosis. OBJECTIVE: To quantify the frequency of germline DNA repair gene mutations in UK PCa cases and controls, in order to more comprehensively evaluate the contribution of individual genes to overall PCa risk and likelihood of aggressive disease. DESIGN, SETTING, AND PARTICIPANTS: We sequenced 167 DNA repair and eight PCa candidate genes in a UK-based cohort of 1281 young-onset PCa cases (diagnosed at ≤60yr) and 1160 selected controls. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Gene-level SKAT-O and gene-set adaptive combination of p values (ADA) analyses were performed separately for cases versus controls, and aggressive (Gleason score ≥8, n=201) versus nonaggressive (Gleason score ≤7, n=1048) cases. RESULTS AND LIMITATIONS: We identified 233 unique protein truncating variants (PTVs) with minor allele frequency <0.5% in controls in 97 genes. The total proportion of PTV carriers was higher in cases than in controls (15% vs 12%, odds ratio [OR]=1.29, 95% confidence interval [CI] 1.01-1.64, p=0.036). Gene-level analyses selected NBN (pSKAT-O=2.4×10-4) for overall risk and XPC (pSKAT-O=1.6×10-4) for aggressive disease, both at candidate-level significance (p<3.1×10-4 and p<3.4×10-4, respectively). Gene-set analysis identified a subset of 20 genes associated with increased PCa risk (OR=3.2, 95% CI 2.1-4.8, pADA=4.1×10-3) and four genes that increased risk of aggressive disease (OR=11.2, 95% CI 4.6-27.7, pADA=5.6×10-3), three of which overlap the predisposition gene set. CONCLUSIONS: The union of the gene-level and gene-set-level analyses identified 23 unique DNA repair genes associated with PCa predisposition or risk of aggressive disease. These findings will help facilitate the development of a PCa-specific sequencing panel with both predictive and prognostic potential. PATIENT SUMMARY: This large sequencing study assessed the rate of inherited DNA repair gene mutations between prostate cancer patients and disease-free men. A panel of 23 genes was identified, which may improve risk prediction or treatment pathways in future clinical practice.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Leongamornlert DA, Saunders EJ, Wakerell S, et al. Germline DNA Repair Gene Mutations in Young-onset Prostate Cancer Cases in the UK: Evidence for a More Extensive Genetic Panel. Eur Urol. 2019. PMID: 30777372. doi:10.1016/j.eururo.2019.01.050

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。